Memorial Sloan-Kettering Cancer Center confirms the human immunomodulatory effects of maitake extract manufactured under Yukiguni’s US #5,854,404 patent

2008-7-16 - Yukiguni Maitake Company, Ltd.

Memorial Sloan-Kettering Cancer Center (“MSKCC”) recently announced at the Annual Meeting of American Society of Clinical Oncology (ASCO) in Chicago, that the results of an ongoing clinical trial confirm the immunomodulatory effects of maitake (grifola frondosa) extract produced under US patent number #5,854,404 and Japanese patent number #2,859,843, both of which are owned by Yukiguni Maitake.

For the detailed analysis, please click here.

 Kazunori Kameyama, CEO of Yukiguni Maitake Corporation of America , said, “Since MSKCC started its research on maitake in 2001, it has been using the maitake extract produced under US patent #5,854,404.”

  “Yukiguni Maitake is proud that the extract produced through its manufacturing patent has been used in the study at an institution of such high caliber, and we are confident that our ISO and Kosher certified maitake extract can respond to the highest requirements in any clinical research through its proven high quality.”

 Yukiguni’s patented maitake extract is available in the US through its American sales affiliate, The Tradeworks Group inc.

 For information about the maitake extract used in the research, visit  http://www.maitakegold.com/